Health · 50 views
An RNA molecule contributes to therapy resistance of triple negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Chemotherapy before or after surgery remains the standard treatment regimen for stage I–III TNBC.
AI Summary
Researchers found that a specific RNA molecule helps triple‑negative breast cancer cells resist chemotherapy. The study focused on stage I–III TNBC, where surgery and chemotherapy are standard, and noted that only a minority of patients respond to PARP‑inhibitor targeted therapy due to BRCA mutations.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Hemoglobin component heme shown to inhibit enzyme that helps dissolve blood clotsContinue reading
- How dismissed symptoms can push patients to breaking pointContinue reading
- Overwhelmed by parenting? You've got plenty of companyContinue reading
- Want to lose weight? Don't skip the weightsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow